• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

    1/6/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email

    BOSTON, Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time.

    The public may access Mr. Simon's presentation live via audio webcast at:

    https://jpmorgan.metameetings.net/events/healthcare25/sessions/58190-haemonetics-corporation/webcast?gpu_only=true&kiosk=true 

    The live webcast can also be accessed under the Events & Presentations section of Haemonetics' Investor Relations website. The replay of the presentation will be available for 30 days using the link provided above and on Haemonetics' Investor Relations website beginning approximately one hour after completion of the live event.

    ABOUT HAEMONETICS

    Haemonetics (NYSE:HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

    Investor Contacts:                                              



    Olga Guyette, Vice President-Investor Relations & Treasury     

    David Trenk, Manager-Investor Relations

    (781) 356-9763                                                                         

    (203) 733-4987

    [email protected]                                           

    [email protected]                                                                                





    Media Contact:                                                           



    Josh Gitelson, Sr. Director-Global Communications       



    (781) 356-9776



    [email protected] 



    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302342258.html

    SOURCE Haemonetics Corporation

    Get the next $HAE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    12/6/2024$116.00Overweight
    Analyst
    11/8/2024$120.00Outperform → Strong Buy
    Raymond James
    9/13/2024$116.00Buy
    CL King
    9/11/2024$85.00Neutral
    BofA Securities
    9/10/2024$112.00Buy
    BTIG Research
    6/12/2024$112.00Hold → Buy
    Needham
    10/13/2022$90.00Buy
    Mizuho
    More analyst ratings

    $HAE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: EVP and General Counsel Basil Michelle L was granted 6,755 shares, increasing direct ownership by 24% to 35,233 units (SEC Form 4)

      4/A - HAEMONETICS CORP (0000313143) (Issuer)

      6/13/25 4:26:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Amendment: EVP, Chief Commercial Officer Galvin Roy was granted 5,689 shares, increasing direct ownership by 79% to 12,932 units (SEC Form 4)

      4/A - HAEMONETICS CORP (0000313143) (Issuer)

      6/13/25 4:21:06 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SVP, Human Resources Miller Laurie A. was granted 3,195 shares, increasing direct ownership by 12% to 29,163 units (SEC Form 4)

      4 - HAEMONETICS CORP (0000313143) (Issuer)

      6/9/25 4:54:35 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      BOSTON, May 30, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:40 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1721260&tp_key=3096fdc651&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be availab

      5/30/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

      First fully absorbable, sutureless closure system designed for large-bore procedures aims to improve procedural efficiency and patient outcomes in structural heart interventions Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced European CE mark approval of the PerQseal® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer. Leveraging Vivasure's PerQseal technology, the PerQseal Elite vascular closure system is designed exclusively for sutureless and fully absorbable large-bore closure follow

      4/22/25 9:36:00 AM ET
      $HAE
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products

    $HAE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Haemonetics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Haemonetics from Neutral to Underperform and set a new price target of $68.00 from $95.00 previously

      2/7/25 8:24:25 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Analyst initiated coverage on Haemonetics with a new price target

      Analyst initiated coverage of Haemonetics with a rating of Overweight and set a new price target of $116.00

      12/6/24 7:49:19 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics upgraded by Raymond James with a new price target

      Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00

      11/8/24 7:51:25 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care